EuroBiotech: More Articles of Note

Newspapers

> 4SC licensed Kv1.3 inhibitors to Maruho. The deal could net 4SC more than €200 million ($230 million) in milestones if Maruho turns the preclinical compound class into a commercial product. Statement

> One Nucleus named Toby Jones as its chief executive. The Cambridge, U.K.-based life science membership organization is promoting Jones to replace outgoing leader Harriet Fear. Release

> Targovax sold about 320,000 of the 2 million shares it offered. Statement

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Can-Fite took a step toward enrolling patients in its phase 2 non-alcoholic fatty liver disease trial by completing the investigator meeting. The three-arm, 60-patient clinical trial is assessing the effect of namodenoson on liver triglyceride concentrations. Release

> Paion raised €8 million ($9 million) in a private placement. The German specialty pharma company plans to use the money to prepare for a European phase 3 trial of remimazolam in general anesthesia. Statement

> BrainStorm Cell Therapeutics enlisted Massachusetts General Hospital and California Pacific Medical Center to enroll patients in a phase 3 trial of its amyotrophic lateral sclerosis candidate. Release

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.